This study examined whether GABAergic inhibitory interneurons can oppose neuronal activity-driven glioma growth in adult glioma, using genetic and pharmacological enhancement or disruption of inhibitory tone to assess effects on tumor proliferation and survival.
Enhancing inhibitory tone (genetically or pharmacologically) restrained tumor proliferation and prolonged survival, while disrupting inhibitory synaptic output accelerated growth; mechanistically, GABAergic input suppressed tumor calcium dynamics, attenuating YAP1 and mTOR oncogenic signaling.
Findings are primarily mechanistic/preclinical — clinical translatability to human glioma patients is not yet established. Specific pharmacological agents, dosing, and human outcome data are not reported in the abstract. The balance between inhibitory and excitatory circuit influences in diverse glioma subtypes is not fully characterized.
Inhibitory circuit activity may act as a tumor-suppressive signal in adult glioma — strategies that strengthen GABAergic tone (e.g., GABAergic pharmacology) warrant investigation as adjunct therapies. Clinicians should be aware that the glioma microenvironment is shaped by a balance of excitatory and inhibitory neural inputs, not excitatory drive alone.
Explore related topics
